source
- Option-to-acquire structures stay uncommon amid biotech's busy M&A seasonBiotech companies are experiencing one of the busiest deal-making years on record, with a flood of announced mergers and acquisitions. Two recent transactions have highlighted the option-to-acquir…
- FDA clears Roche and Lilly Alzheimer’s blood tests, while Regenxbio gene therapy trial halted againThe U.S. Food and Drug Administration announced it has granted clearance for blood-based diagnostic tests for Alzheimer’s disease developed by Roche and Eli Lilly. The clearances allow the compani…